Trials / Recruiting
RecruitingNCT07166211
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With CSU
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM512 injection | subcutaneous injection |
| DRUG | placebo | subcutaneous injection |
Timeline
- Start date
- 2025-11-27
- Primary completion
- 2026-11-02
- Completion
- 2027-01-14
- First posted
- 2025-09-10
- Last updated
- 2026-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07166211. Inclusion in this directory is not an endorsement.